Real-World Evidence Conference

This panel brings together leading voices from academia, industry, and regulatory science—Nancy A. Dreyer, Sebastian Schneeweiss, Khaled Sarsour, and Marie Bradley—to explore how real-world evidence is reshaping the future of drug development, regulatory decision-making, and patient access. Drawing on diverse perspectives, the discussion will examine evolving methodological standards, data reliability, and the increasing expectations for RWE in global regulatory frameworks. Panelists will highlight emerging use cases across the product lifecycle, from early development to post-market evaluation, and address barriers to broader adoption. Attendees will gain forward-looking insights into how to operationalize RWE strategies that align with scientific rigor and regulatory requirements in a rapidly evolving landscape.